Oncology Xagena
The pivotal phase 3 KEYNOTE-426 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Axitinib ( Inlyta ), tyrosine kinase inhibitor, met both primary endpoints of ...
The randomized, open-label, phase 3 KEYNOTE-426 study has demonstrated that Pembrolizumab ( Keytruda ) + Axitinib ( Inlyta ) significantly improved overall survival ( OS ), progression-free survival ( ...
